Phase II data show 12-week efficacy of varenicline nasal spray in dry eye disease
- Posted on: Feb 4 2022
- Leave a response
The phase II MYSTIC clinical trial for the small-molecule nicotinic acetylcholine receptor agonist varenicline nasal spray (VNS), showed rapid onset of tear production and immediate relief reported by patients with dry eye disease.
Source: AAO
Posted in: Uncategorized
